{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:38:27Z","timestamp":1707525507065},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,10]]},"DOI":"10.7759\/cureus.50273","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T14:59:05Z","timestamp":1702220345000},"source":"Crossref","is-referenced-by-count":0,"title":["Apixaban (Eliquis)-Induced Rash: A Case Report"],"prefix":"10.7759","author":[{"given":"Harshita","family":"Nadella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Vilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Nochimson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Apixaban","author":"Agrawal A","year":"2023","unstructured":"Agrawal A, Kerndt C, Manna B. Apixaban. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-022-06051-7","article-title":"The safety and efficacy of apixaban (Eliquis) in 5017 post-bariatric patients with 95.3% follow-up: a multicenter study","volume":"32","author":"Surve A","year":"2022","unstructured":"Surve A, Potts J, Cottam D, et al.. The safety and efficacy of apixaban (Eliquis) in 5017 post-bariatric patients with 95.3% follow-up: a multicenter study. Obes Surg. 2022, 32:1-6. 10.1007\/s11695-022-06051-7","journal-title":"Obes Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44376","article-title":"Cutaneous leukocytoclastic vasculitis induced by apixaban and\/or rivaroxaban with seronegative anti-neutrophil cytoplasmic antibody (ANCA) titers: a case report and literature review","volume":"15","author":"El-Sabbagh M","year":"2023","unstructured":"El-Sabbagh M, Rifai S, Sabah ZM, Tarakji AM, Rifai AO, Dahan S, Denig KM. Cutaneous leukocytoclastic vasculitis induced by apixaban and\/or rivaroxaban with seronegative anti-neutrophil cytoplasmic antibody (ANCA) titers: a case report and literature review. Cureus. 2023, 15:e44376. 10.7759\/cureus.44376","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa182","article-title":"Possible apixaban-induced leukocytoclastic vasculitis","volume":"77","author":"Daul B","year":"2020","unstructured":"Daul B, Petersen G, Butler J. Possible apixaban-induced leukocytoclastic vasculitis. Am J Health Syst Pharm. 2020, 77:1389-92. 10.1093\/ajhp\/zxaa182","journal-title":"Am J Health Syst Pharm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0897190017722872","article-title":"Probable rivaroxaban-induced full body rash: a case report","volume":"31","author":"Sasson E","year":"2018","unstructured":"Sasson E, James M, Russell M, Todorov D, Cohen H. Probable rivaroxaban-induced full body rash: a case report. J Pharm Pract. 2018, 31:503-6. 10.1177\/0897190017722872","journal-title":"J Pharm Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S325430","article-title":"Anti-Xa inhibitor-induced hemorrhagic pruritic rash: a case report on possible cross-reactivity between apixaban and rivaroxaban","volume":"13","author":"Anis TR","year":"2021","unstructured":"Anis TR, Jandreau W. Anti-Xa inhibitor-induced hemorrhagic pruritic rash: a case report on possible cross-reactivity between apixaban and rivaroxaban. Clin Pharmacol. 2021, 13:181-4. 10.2147\/CPAA.S325430","journal-title":"Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2016.6774","article-title":"A rare side effect seen due to the use of apixaban: palmoplantar psoriasiform drug eruption","volume":"16","author":"Veliyev V","year":"2016","unstructured":"Veliyev V, \u00d6zmen \u0130, Ya\u015far S, G\u00fcrsoy E, K\u00f6kl\u00fc M, \u00c7elik M. A rare side effect seen due to the use of apixaban: palmoplantar psoriasiform drug eruption. Anatol J Cardiol. 2016, 16:213-5. 10.14744\/AnatolJCardiol.2016.6774","journal-title":"Anatol J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3561","article-title":"Chapter 28: classification of hypersensitivity reactions","volume":"33 Suppl 1","author":"Uzzaman A","year":"2012","unstructured":"Uzzaman A, Cho SH. Chapter 28: classification of hypersensitivity reactions. Allergy Asthma Proc. 2012, 33 Suppl 1:96-9. 10.2500\/aap.2012.33.3561","journal-title":"Allergy Asthma Proc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204278-apixaban-eliquis-induced-rash-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:33Z","timestamp":1707509373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204278-apixaban-eliquis-induced-rash-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,10]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.50273","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,10]]}}}